Nu-Med Plus Financials

No, Nu-Med Plus (NUMD) reported a net income of -$68K in fiscal year 2024.

Nu-Med Plus (NUMD) reported diluted earnings per share of $0.00 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nu-Med Plus (NUMD) had EBITDA of -$63K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Nu-Med Plus (NUMD) generated -$4K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Nu-Med Plus (NUMD) had $9K in total assets as of fiscal year 2024, including both current and long-term assets.

Nu-Med Plus (NUMD) had 84M shares outstanding as of fiscal year 2024.

Nu-Med Plus (NUMD) had a current ratio of 0.04 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Nu-Med Plus (NUMD) had a debt-to-equity ratio of -1.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Nu-Med Plus (NUMD) had a return on assets of -729.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Nu-Med Plus (NUMD) had $2K in cash against an annual operating cash burn of $4K. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Nu-Med Plus (NUMD) has negative shareholder equity of -$215K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Nu-Med Plus (NUMD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nu-Med Plus (NUMD) has an earnings quality ratio of 0.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Nu-Med Plus (NUMD) has an interest coverage ratio of -12.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.